References
Tsang RY, Al-Fayea T, Au H-J. Cisplatin overdose: toxicities and management. Drug Saf 2009; 32(12): 1109–22
Gandhi TK, Bartel SB, Shulman LN, et al. Medication safety in the ambulatory chemotherapy setting. Cancer 2005 Dec 1; 104(11): 2477–83
Muller T. Typical medication errors in oncology: analysis and prevention strategies. Onkologie 2003 Dec; 26(6): 539–44
Huertas Fernandez MJ, Baena-Canada JM, Martinez Bautista MJ, et al. Impact of computerised chemotherapy prescriptions on the prevention of medication errors. Clin Transl Oncol 2006 Nov; 8(11): 821–5
Schulmeister L. Preventing chemotherapy errors. Oncologist 2006 May; 11(5): 463–8
Voeffray M, Pannatier A, Stupp R, et al. Effect of computerisation on the quality and safety of chemotherapy prescription. Qual Saf Health Care 2006 Dec; 15(6): 418–21
Chu G, Mantin R, Shen YM, et al. Massive cisplatin overdose by accidental substitution for carboplatin: toxicity and management. Cancer 1993 Dec 15; 72(12): 3707–14
Jung HK, Lee J, Lee SN. A case of massive cisplatin overdose managed by plasmapheresis. Korean J Intern Med 1995 Jul; 10(2): 150–4
Vila-Torres E, Albert-Mari A, Almenar-Cubells D, et al. Case report: cisplatin preparation error; patient management and morbidity. J Oncol Pharm Pract 2009 Dec; 15(4): 249–53
Dentino M, Luft FC, Yum MN, et al. Long term effect of cisdiamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978 Apr; 41(4): 1274–81
Blachley JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981 Nov; 95(5): 628–32
Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985 Oct; 3(10): 1379–84
Pike IM, Arbus MH. Cisplatin overdosage. J Clin Oncol 1992 Sep; 10(9): 1503–4
Pourrat X, Antier D, Crenn I, et al. A prescription and administration error of cisplatin: a case report. Pharm World Sci 2004 Apr; 26(2): 64–5
Schiller JH, Rozental J, Tutsch KD, et al. Inadvertent administration of 480 mg/m2 of cisplatin. Am J Med 1989 May; 86(5): 624–5
Ethyol® (amifostine for injection): US prescribing information. Gaithersburg (MD): MedImmune, LLC, 2009 Jan
Albers J, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2007 Jan; (1): CD005228
British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 59. London: BMJ Publishing Group Ltd and RPS Publishing, 2010 Mar
Rights and permissions
About this article
Cite this article
Manage cisplatin overdose with a rational and systematic approach. Drugs Ther. Perspect 26, 23–26 (2010). https://doi.org/10.2165/11205350-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11205350-000000000-00000